The multifaceted nature of fibromyalgia presents challenges in diagnosis and management, often coexisting with conditions ...

Dec. 22, 2023 — There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia. Both forms of treatment produced a ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its ...

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...

The following is a summary of “Fibromyalgia severity and symptoms are associated with the disorders of gut–brain interaction, ...

Growing awareness about fibromyalgia and advancements in treatment options drive market growth. Generic Medication Accessibility: Enhanced availability of generic medications for fibromyalgia ...

The FDA has accepted the NDA for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

A new finding of post-exertional malaise in 20% of people with fibromyalgia might be an overestimate, but when ...

The following is a summary of “Pain sensitization in fibromyalgia. Cross-sectional associations between quantitative sensory ...

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, assigned a Prescription Drug User Fee Act, PDUFA, goal ...

Tonix Pharmaceuticals Holding Corp. recently revealed in an 8-K filing with the U.S. Securities and Exchange Commission that the U.S. Food and Drug Administration (FDA) has set a Prescription Drug ...